Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study
Sujit Sheth(Columbia University Irving Medical Center), Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonis Kattamis, Natalia Holot(Bristol-Myers Squibb (United States)), Kevin H.M. Kuo(University Health Network), Olivier Hermine(Centre National de la Recherche Scientifique), Alì Taher(American University of Beirut Medical Center), Thomas D. Coates(Children's Hospital of Los Angeles), Wen‐Ling Kuo(Chang Gung University), Antonio Piga, Loyse Felber Medlin(Bristol-Myers Squibb (Switzerland)), John B. Porter(Royal London Hospital)
Cited by 8
Related Papers
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777
Thalassaemia
|The Lancet|2017|763
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
|New England Journal of Medicine|2007|520